Dublin, June 27, 2019 (GLOBE NEWSWIRE) -- The "Ninlaro" report has been added to ResearchAndMarkets.com's offering.
Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.
Preclinical studies suggest that Ninlaro demonstrates a stronger anti-tumor effect than Velcade (bortezomib; Takeda/Johnson & Johnson).
Key Topics Covered
- Drug Overview
- Product Profiles
- Ninlaro : Multiple myeloma
List of Figures
Figure 1: Ninlaro for multiple myeloma - SWOT analysis
Figure 2: The authors drug assessment summary of Ninlaro for multiple myeloma
Figure 3: The authors drug assessment summary of Ninlaro for multiple myeloma
Figure 4: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Ninlaro drug profile
Table 2: Ninlaro pivotal trial data in multiple myeloma
Table 3: Ninlaro ongoing late-phase clinical trials in multiple myeloma
Table 4: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Patients treated with Ninlaro across the US, Japan, and five major EU markets, by country, 2017-26
For more information about this report visit https://www.researchandmarkets.com/r/fzkq38
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.